Impact of autologous stem cell transplantation on survival outcomes in patients with peripheral T cell lymphoma

Guren C. U., TOPTAŞ T., MEHTAP Ö., Yılmaz G., Polat G., ORUÇ Ö., ...Daha Fazla

Transfusion and Apheresis Science, cilt.61, sa.6, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 61 Sayı: 6
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.transci.2022.103514
  • Dergi Adı: Transfusion and Apheresis Science
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Anahtar Kelimeler: Peripheral T cell lymphoma, Autologous stem cell transplantation, Prognosis of peripheral T cell lymphoma, NON-HODGKIN-LYMPHOMA, PROGNOSTIC-FACTORS, CONSOLIDATION, PTCL
  • Marmara Üniversitesi Adresli: Evet

Özet

© 2022 Elsevier LtdData about the timing of autologous stem cell transplantation (ASCT) in peripheral T cell lymphoma (PTCL) are conflicting. We aimed to investigate the impact of the sequence of ASCT on the survival outcomes in patients with PTCL. Analyzes were performed retrospectively in a total of 81 patients, 16 of whom underwent upfront ASCT and 12 received salvage ASCT. In univariate analysis, upfront ASCT reduced the risk of progression and death by 77% (Hazard ratio (HR): 0.23, 95% confidence interval (CI): 0.09–0.60) (p = 0.003) and by 84% (HR: 0.16, 95% CI: 0.5–0.55) (p = 0.003), respectively. However, in multivariate analysis, only salvage ASCT predicted a more favorable progression-free and overall survival (HR: 0.17, 95% CI: 0.06–0.48, p = 0.001 and HR: 0.20, %95 GA: 0.06–0.62, p = 0.005, respectively). In conclusion, regardless of first-line therapy, patients have more favorable outcomes if they receive salvage ASCT. Upfront ASCT does not add clinically significant benefit to survival outcomes.